Tokyo, June 7, 2006 (JCN) - Otsuka Pharmaceutical announced on June 6 that it will begin shipping Abilify, its proprietary antipsychotic agent, in Japan on June 8. Abilify (aripiprazole), a dopamine partial agonist, which has a different action mechanism from the conventional antipsychotics, is a new option for schizophrenia.
